Tianjin Medical University Cancer Institute and Hospital
A multicenter randomized phase Ⅲ clinical trial of gemcitabine in combination with capecitabine versus gemcitabine plus carboplatin as first-line treatment in triple-negative recurrent or metastatic breast cancer.The primary endpoints of the study is progression free survival (PFS). The secondary endpoints are overall response rate (ORR), overall survival (OS) and safety.
Age
18–70
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Female
18-70 years old
ECOG 0-1
Expected lifetime more than 12 weeks
You may not be if
Pregnancy
Brain Metastasis,
Severe Infection
Clareo Health | Trial of Gemcitabine_Capecitabine Versus Gemcitabine_Carboplatin in Breast Cancer
